Akademik Veri Yönetim Sistemi
TURKISH ACADEMIC RESEARCH REVIEW INTERNATIONAL MULTIDISCIPLINARY CONGRESS, Antalya, Türkiye, 12 - 14 Ekim 2018
Lung cancer is the third most common cancer in the world with highest cancer mortality
rate. From the radiotherapeutical aspect, genomic variations and imaging fenotypes
in cancer patients that predicts response to radiation and it’s toxicities are called
radiogenomics (RG). Since 2009, The Radiogenomics Consortium (RgC) researchs for
differencies in radiosensitivity and adverse effects of radiotherapy. Their REQUITE
Project, prospectively collects the data from 5300 lung, breast and prostate cancer patients
in order to validate predictive tests for normal tissue radiosensitivity. Additionally, The
Cancer Genome Atlas (TCGA) Research Network marked the end of the TCGA program
by publishing the Pan-Cancer Atlas in April 2018. This atlas is informing new strategies
for future therapeutic developments with comprehensive integrative molecular analyses
of tumors. In Non-small cell lung cancer (NSCLC) patients, extraction of sub-visual
images and genetical alterations related to these features seems to be effect NSCLC
treatment strategies. Estimating EGFR mutations from pre-treatment CT and/or PET
scans with mixture of volume, texture and gradient features is still under use in some
clinical protocols. Some relations between ALK, ROS1, RET mutations and imaging
features like tumor location and/or pleural effusions are also found in some of the other
trials. These mutations are causes to proliferation, differentiation, migration of the
tumor in some degrees with shortened patient survival. Gene-based predictive tests for
radiosensitivity in NSCLC, will provide treatment decisions regarding radiation dose
escalation or de-escalation, use of novel drugs and selection of the most appropiate
treatment modality. Thus, detailed and meticulous evaluations of the radiological images becomes more important in this new era. The importance of RG, is to provide
individualised treatment models increasing the efficacy of the RT while, diminishing it’s
toxicities. Moreover, decisions for stereotactic RT, re-irradiation and other special RT
applications seems to be based on RG in the near future.
Keywords: Radiogenomics, Non-Small Cell Lung Cancer, Radiotherapy